688366.SH
Shanghai Haohai Biological Technology Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 29.45
−6.21%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.3B | 2.5B | 2.7B | 2.7B | 2.1B |
| Cost of Revenue | 787.7M | 738.8M | 812.6M | 782.8M | 660.8M |
| Gross Profit | 1.6B | 1.7B | 1.9B | 1.9B | 1.5B |
| Operating Expenses | |||||
| R&D Expense | 191.6M | 197.8M | 238.9M | 220.1M | 182.2M |
| SG&A Expense | 283.8M | — | — | — | — |
| General & Admin Expense | 309.5M | 428.7M | 442.7M | 417.8M | 402.3M |
| Selling & Marketing Expense | 584.4M | 814.8M | 780.8M | 814.5M | 679.5M |
| Other Expenses | 24.2M | — | — | — | — |
| Total Operating Expenses | 1.4B | 1.4B | 1.4B | 1.4B | 1.2B |
| Cost and Expenses | 2.2B | 2.1B | 2.2B | 2.2B | 1.9B |
| Operating Income (EBIT) | 91.5M | 220.2M | 494.8M | 507.4M | 234.6M |
| Non-Operating | |||||
| Interest Income | 12.5M | — | — | — | — |
| Interest Expense | 2.6M | — | — | — | — |
| Net Interest Income | 9.9M | — | — | — | — |
| Other Non-Op Income/Expense | 24.9M | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 136.0M | 239.2M | 466.1M | 508.3M | 235.7M |
| Income Tax Expense | 19.0M | 30.9M | 89.9M | 96.0M | 45.4M |
| Bottom Line | |||||
| Net Income | 152.4M | 251.0M | 420.4M | 416.1M | 180.5M |
| Earnings from Cont. Ops | 117.0M | 208.3M | 376.2M | 412.3M | 190.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 152.4M | 251.0M | 420.4M | 416.1M | 180.5M |
| Per Share | |||||
| Basic EPS | CN¥0.66 | CN¥1.08 | CN¥1.80 | CN¥1.75 | CN¥1.04 |
| Diluted EPS | CN¥0.66 | CN¥1.08 | CN¥1.80 | CN¥1.75 | CN¥1.04 |
| Revenue Per Share | CN¥10.43 | CN¥10.64 | CN¥11.55 | CN¥11.16 | CN¥12.28 |
| Shares | |||||
| Basic Shares Outstanding | 224.8M | 232.4M | 233.6M | 237.8M | 173.5M |
| Diluted Shares Outstanding | 224.8M | 232.4M | 233.6M | 237.8M | 173.5M |
| Profitability Metrics | |||||
| EBITDA | 68.0M | 403.3M | 675.6M | 683.3M | 419.0M |
| D&A | 56.8M | 183.1M | 180.9M | 175.9M | 184.4M |
| EBIT | 11.2M | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026